Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market

Iveric Bio is coming for Apellis Pharmaceuticals. Tuesday, the biotech revealed its second late-phase geographic atrophy clinical trial has hit its primary endpoint and outlined plans to file for FDA approval in the eye disease by the end of the first quarter.